studies

mML - L1 - BRAF wild, Immune checkpoint association vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsCheckMate 069 (BRAF wild type), 2015 0.40 [0.23; 0.69] 0.40[0.23; 0.69]CheckMate 069 (BRAF wild type), 201510%109NAnot evaluable objective responses (ORR)detailed resultsCheckMate 069 (BRAF wild type), 2015 12.96 [3.47; 48.38] 12.96[3.47; 48.38]CheckMate 069 (BRAF wild type), 201510%109NAnot evaluable objective responses (ORR) (extension)detailed resultsCheckMate 069 (BRAF wild type), 2015 13.00 [3.48; 48.60] 13.00[3.48; 48.60]CheckMate 069 (BRAF wild type), 201510%109NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 069 (BRAF wild type), 2015 3.39 [1.40; 8.19] 3.39[1.40; 8.19]CheckMate 069 (BRAF wild type), 201510%108NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-06-01 13:57 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 128 - treatments: 856,634,861,416,864,769,980

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons